Miroslav Šašinka, Katarína Furková
Last years have brought fundamental changes in elucidation of pathogenesis of children vasculitis reflecting in their new classification, development of mew markers (endothelial microparticules, circulating mature endothelial cells) that enable to follow disease activity and therapy effectiveness and work up new effective therapeutic procedures. These procedures enabled to cut down relatively risk use of cyclophosphamid and corticoids in children and increase the use of mycofenolate and biological therapy (infliximab, rituximab, analogues of thalidomid). The stage of renal impairment decides on final faith of a child with vasculitis. The authors of the article summarize all new knowledge and confront it with observations of their own patients.